GlaxoSmithKline already partners with Vectura on respiratory therapies, but some say the British pharma giant could be looking to take the pair’s relationship one step further.
Glaxo is preparing a 175-pence-per-share bid for the Chippenham, U.K.-based company, sources told The Telegraph. That offer would value Vectura at close to £1.2 billion.
If GSK does strike, it’ll be taking advantage of Vectura’s 2017 share price drop. In May, the FDA turned down a generic of GlaxoSmithKline blockbuster Advair from Vectura and partner Hikma, and investors have continued to pressure the stock as they await a final verdict from the regulatory agency, due this quarter, the newspaper notes.
And last week’s investment strategy update didn’t sit particularly well with shareholders, either. In it, Vectura said it would increase its focus on lower-risk pipeline development opportunities and “cease” investment in “relatively higher risk, novel molecule, early stage programs,” instead looking for partnerships in that arena.
Glaxo knows what it would be getting itself into with a Vectura buy. The drugmaker licensed Vectura’s technology for products such as Breo and Anoro, and Vectura boasts some “smart inhaler” technology that GSK may be interested in, too, The Telegraph notes.
While CEO Emma Walmsley has made clear that reviving Glaxo’s pharma portfolio is a top priority,, right now all eyes are on the company’s consumer unit—at least when it comes to M&A. GSK is weighing a bid for Pfizer’s on-the-block OTC division, along with rivals including Reckitt Benckiser.
By Carly Helfand
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
